Invesco Ltd. - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 114 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$900,808
+64.7%
104,381
+97.5%
0.00%
Q2 2023$547,009
-4.0%
52,851
+0.7%
0.00%
Q1 2023$569,647
+77.5%
52,502
+83.6%
0.00%
Q4 2022$320,915
+8.4%
28,602
-1.7%
0.00%
Q3 2022$296,000
+24.4%
29,098
+10.7%
0.00%
Q2 2022$238,000
-4.0%
26,281
+1.4%
0.00%
Q1 2022$248,000
-12.7%
25,908
+0.7%
0.00%
Q4 2021$284,000
+40.6%
25,729
-5.6%
0.00%
Q3 2021$202,000
-36.3%
27,252
+24.9%
0.00%
Q2 2021$317,000
+26.3%
21,812
+77.3%
0.00%
Q1 2021$251,000
+40.2%
12,304
+22.6%
0.00%
Q4 2020$179,000
-69.5%
10,033
-60.5%
0.00%
Q1 2020$587,000
+96.3%
25,408
+92.6%
0.00%
Q1 2019$299,000
-53.2%
13,190
-47.2%
0.00%
Q4 2018$639,000
-24.5%
24,978
-3.6%
0.00%
Q3 2018$846,000
+67.9%
25,904
+16.7%
0.00%
Q2 2018$504,000
+80.6%
22,204
+92.9%
0.00%
Q1 2018$279,000
+36.8%
11,509
+57.4%
0.00%
Q4 2017$204,000
-89.5%
7,311
-87.1%
0.00%
-100.0%
Q3 2017$1,947,000
+648.8%
56,860
+770.9%
0.00%
Q2 2017$260,000
+7.9%
6,529
-0.4%
0.00%
Q1 2017$241,000
-82.6%
6,552
-84.9%
0.00%
Q4 2016$1,384,000
-57.6%
43,411
-51.8%
0.00%
-100.0%
Q3 2016$3,267,000
+65240.0%
90,152
+24069.4%
0.00%
Q2 2015$5,0003730.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2023
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders